NVTA / Down 97%, Is It Finally Time to Buy Invitae Stock?

Invitae's stock is down and it might get delisted from its stock exchange. It has a new crop of top managers, but it's running low on cash. more_horizontal

Invitae's revenue has climbed over time thanks to a vast portfolio of genetic tests. At the same time, the company has struggled to turn that into pro more_horizontal

Late Friday, the U.S. FDA granted De Novo marketing authorization for the Invitae Common Hereditary Cancers Panel. The panel is the first of its kind more_horizontal

Invitae (NYSE: NVTA ) stock is on the rise Monday despite a lack of news from the medical genetics company this morning. There haven't been any new pr more_horizontal

Invitae has struggled to turn rising revenue into profit. Last year, the company launched a strategic plan to pave the way to positive cash flow and i more_horizontal

Stock market analysts have conflicting opinions about the market value of this genetic testing business. Worth more than $10 billion at its peak, beat more_horizontal

Invitae (NVTA) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy). more_horizontal

Popular investment manager Cathie Wood is known for investing in innovative growth stocks. more_horizontal